SUO Annual Meeting

“I believe that this is, of course,…a harbinger of what is to come—those of underserved backgrounds being…featured [more] in our organizations,” says Curtis A. Pettaway, MD.

“The SUO has never been stronger in its ability to deliver on clinical trials,” says Michael S. Cookson, MD, MMHC, FACS.

"Although, as urologic oncologists, we all see a few cases in our practices individually, I think, no question, there's a lot of heterogeneity in how penile cancer is managed across the United States," says Philippe E. Spiess, MD, MS.

“We're really moving into not just these annual meetings, but we're going to have some programs throughout the year that will be targeted towards…really important, impactful research that comes out,” says Michael S. Cookson, MD, MMHC, FACS.

“New regimens should now start to be explored, both…single-agent drugs as well as combination therapies,” says Pavlos Msaouel, MD, PhD.

“[It’s] important to see all of these…clinically important endpoints going in the same direction,” says Matthew D. Galsky, MD.

“It was incredibly humbling,” says Eila C. Skinner, MD.

“This category of therapeutic is fairly well-tolerated; safe to give,” says Mohummad M. Siddiqui MD.

“We still debate and there’s some good data that [supports that] chemotherapy is not that effective for patients with penile cancer,” says Philippe E. Spiess, MD, MS, FACS.

“We’re just getting one step closer to being able to find urine tests that we can use to help risk stratify patients, and then help understand the genetic profiles of other tumors, which might help guide management later on,” says Wesley Yip, MD.

Pavlos Msaouel, MD, PhD, discusses the latest developments with adjuvant therapy in nonmetastatic renal cell carcinoma.

“We found that, overall, segmental ureterectomy patients actually did better in terms of overall survival,” says Siv Venkat, MD, FRCSC.

Urine cytology specimen NGS was found to be a feasible and valid method of assessing genomic alterations in patients with upper tract urothelial carcinoma.

Findings presented at the 2021 Society of Urologic Oncology Annual Meeting demonstrate that segmental ureterectomy may be comparable to radical nephroureterectomy.

The investigators found that the overall upstaging rate from re-TURBT to RC was 34.9%, with 31.0% upstaged in the NAC group and 37.0% in the no-NAC group (P = .584).

“[I focused on] why this such an important topic and how we might better counsel our patients,” says Kristen Scarpato, MD, MPH.

“One of the hardest things and one of the most important things is to figure out what part of urology excites you the most and look for those opportunities,” says Eila C. Skinner, MD.

"I think for the right patient, Cysview technology has a big deliverable,” says Alexander Kutikov, MD, FACS.

“My talk [highlights] unmet research needs that need to be addressed to further improve the adjuvant treatment landscape for our patients,” said Pavlos Msaouel, MD, PhD.

A study examining a broader range of domains among patients receiving cystectomy found a large signal of differences in health-related quality of life.

“No question, we see that there’s a lot of heterogeneity in how penile cancer is managed across the United States,” says Philippe E. Spiess, MD, MS, FACS.

A majority of women were able to return to sexual activity post-surgery without compromising oncological outcomes.

"Some of the discussion going on right now is how to improve the morbidity of bladder cancer treatment by pursuing such things…as bladder sparing approaches when feasible…and so, I think that’s very exciting,” says Mohummad M. Siddiqui, MD.

Recurrence is commonly associated with low-grade upper tract urothelial carcinoma and may be predicted by smoking status and tumor size.

“The idea was really to bring together a multidisciplinary group of experts and to discuss…highly relevant, translational research that’s going on, and to…address some of the really critical clinical questions as well,” says Seth P. Lerner, MD, FACS.

According to extended follow-up from the phase 3 Checkmate 274 trial, nivolumab continued to demonstrate improved disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma.

The primary objective of the study was to assess the benefit of cytoreductive nephrectomy relative to immunotherapy regimens utilizing checkpoint inhibitors.

Phase 1 data suggest the anti–PD-1 immune checkpoint inhibitor is safe and tolerable in the neoadjuvant setting for patients with nonmetastatic high-risk clear cell renal cell carcinoma.

No new safety signals were reported with the androgen receptor pathway inhibitor.

Patients undergoing pouch diversion reported significantly more regret than patients undergoing neobladder or ileal conduit.